Published in J Negat Results Biomed on February 09, 2005
Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum (1994) 14.16
The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis. Arthritis Rheum (1990) 8.67
Regulation of phosphoinositide-specific phospholipase C. Annu Rev Biochem (2001) 6.42
Regulation of phosphoinositide-specific phospholipase C isozymes. J Biol Chem (1997) 3.34
A second type of rat phosphoinositide-specific phospholipase C containing a src-related sequence not essential for phosphoinositide-hydrolyzing activity. J Biol Chem (1989) 2.06
Phospholipase C-gamma is required for agonist-induced Ca2+ entry. Cell (2002) 1.92
Activated neutrophils express proteinase 3 on their plasma membrane in vitro and in vivo. Clin Exp Immunol (1994) 1.61
Alpha 1-antitrypsin genetic polymorphism in ANCA-positive systemic vasculitis. Kidney Int (1993) 1.56
Regulation of the phospholipase C-gamma2 pathway in B cells. Immunol Rev (2000) 1.34
Autoimmunity and inflammation due to a gain-of-function mutation in phospholipase C gamma 2 that specifically increases external Ca2+ entry. Immunity (2005) 1.33
New genomic region for Wegener's granulomatosis as revealed by an extended association screen with 202 apoptosis-related genes. Hum Genet (2004) 1.29
Regulation of B-cell activation and differentiation by the phosphatidylinositol 3-kinase and phospholipase Cgamma pathway. Immunol Rev (2000) 1.20
Proteinase 3 gene polymorphisms and Wegener's granulomatosis. Kidney Int (2000) 1.20
Proteinase 3, Wegener's autoantigen: from gene to antigen. J Leukoc Biol (2001) 1.08
Wegener's granulomatosis. Herz (2004) 1.02
The relation between Staphylococcus aureus and Wegener's granulomatosis: current knowledge and future directions. Intern Med (2003) 0.97
Immunopathology of ANCA-associated vasculitis. Intern Med (1999) 0.96
Staphylococcal acid phosphatase binds to endothelial cells via charge interaction; a pathogenic role in Wegener's granulomatosis? Clin Exp Immunol (2000) 0.86
A genome screen for linkage disequilibrium in HLA-DRB1*15-positive Germans with multiple sclerosis based on 4666 microsatellite markers. Hum Genet (2002) 0.86
Variations in the human phospholipase Cgamma2 gene in patients with B-cell defects of unknown etiology. Immunogenetics (2001) 0.84
Phospholipase C-gamma contains introns shared by src homology 2 domains in many unrelated proteins. Genetics (2003) 0.81
Genetically distinct subsets within ANCA-associated vasculitis. N Engl J Med (2012) 6.93
Netting neutrophils in autoimmune small-vessel vasculitis. Nat Med (2009) 6.72
Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med (2009) 6.61
The development of inflammatory T(H)-17 cells requires interferon-regulatory factor 4. Nat Immunol (2007) 5.83
Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum (2005) 4.21
Granulomatosis with polyangiitis (Wegener's): an alternative name for Wegener's granulomatosis. Arthritis Rheum (2011) 3.60
A vasculitis centre based management strategy leads to improved outcome in eosinophilic granulomatosis and polyangiitis (Churg-Strauss, EGPA): monocentric experiences in 150 patients. Ann Rheum Dis (2012) 2.40
EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis. Ann Rheum Dis (2006) 2.35
Endosomal translocation of vertebrate DNA activates dendritic cells via TLR9-dependent and -independent pathways. J Immunol (2005) 2.02
Eotaxin-3 in Churg-Strauss syndrome: a clinical and immunogenetic study. Rheumatology (Oxford) (2011) 1.74
Prospective long-term follow-up of patients with localised Wegener's granulomatosis: does it occur as persistent disease stage? Ann Rheum Dis (2010) 1.71
Improved outcome in 445 patients with Wegener's granulomatosis in a German vasculitis center over four decades. Arthritis Rheum (2011) 1.60
Mutation of mouse Mayp/Pstpip2 causes a macrophage autoinflammatory disease. Blood (2006) 1.44
Peripheral blood and granuloma CD4(+)CD28(-) T cells are a major source of interferon-gamma and tumor necrosis factor-alpha in Wegener's granulomatosis. Am J Pathol (2002) 1.44
Nonsystemic vasculitic neuropathy: a clinicopathological study of 22 cases. J Rheumatol (2006) 1.39
Felty's syndrome autoantibodies bind to deiminated histones and neutrophil extracellular chromatin traps. Arthritis Rheum (2011) 1.38
Stable incidence of primary systemic vasculitides over five years: results from the German vasculitis register. Arthritis Rheum (2005) 1.36
Two common loss-of-function mutations within the filaggrin gene predispose for early onset of atopic dermatitis. J Invest Dermatol (2006) 1.34
Granulomatosis with polyangiitis (Wegener's): an alternative name for Wegener's granulomatosis. Ann Rheum Dis (2011) 1.33
New genomic region for Wegener's granulomatosis as revealed by an extended association screen with 202 apoptosis-related genes. Hum Genet (2004) 1.29
Cartilage destruction in granulomatosis with polyangiitis (Wegener's granulomatosis) is mediated by human fibroblasts after transplantation into immunodeficient mice. Am J Pathol (2012) 1.29
The PTPN22 620W allele is a risk factor for Wegener's granulomatosis. Arthritis Rheum (2005) 1.27
Neurological involvement in Wegener's granulomatosis. Curr Opin Rheumatol (2011) 1.25
Evaluation of capture ELISA for detection of antineutrophil cytoplasmic antibodies directed against proteinase 3 in Wegener's granulomatosis: first results from a multicentre study. Rheumatology (Oxford) (2003) 1.25
Rituximab for refractory granulomatosis with polyangiitis (Wegener's granulomatosis): comparison of efficacy in granulomatous versus vasculitic manifestations. Ann Rheum Dis (2011) 1.24
Interstitial lung disease in polymyositis and dermatomyositis: clinical course and response to treatment. Semin Arthritis Rheum (2003) 1.24
PGC-1alpha as modifier of onset age in Huntington disease. Mol Neurodegener (2009) 1.22
An EF hand mutation in Stim1 causes premature platelet activation and bleeding in mice. J Clin Invest (2007) 1.20
Effect of Wegener's granulomatosis on work disability, need for medical care, and quality of life in patients younger than 40 years at diagnosis. Arthritis Rheum (2002) 1.20
Clinical manifestations and treatment of Wegener's granulomatosis. Rheum Dis Clin North Am (2010) 1.18
Mitochondrial haplogroup H correlates with ATP levels and age at onset in Huntington disease. J Mol Med (Berl) (2010) 1.13
NR2A and NR2B receptor gene variations modify age at onset in Huntington disease in a sex-specific manner. Hum Genet (2007) 1.13
The SEM6A6 locus is not associated with granulomatosis with polyangiitis or other forms of antineutrophil cytoplasmic antibody-associated vasculitides in Europeans: comment on the article by Xie et al. Arthritis Rheumatol (2014) 1.09
Characterization of phospholipase C gamma enzymes with gain-of-function mutations. J Biol Chem (2009) 1.09
Wegener's granuloma harbors B lymphocytes with specificities against a proinflammatory transmembrane protein and a tetraspanin. J Autoimmun (2010) 1.08
High rate of renal relapse in 71 patients with Wegener's granulomatosis under maintenance of remission with low-dose methotrexate. Arthritis Rheum (2002) 1.07
Alternating 2'-O-ribose methylation is a universal approach for generating non-stimulatory siRNA by acting as TLR7 antagonist. Immunobiology (2009) 1.06
The S18Y polymorphism in the UCHL1 gene is a genetic modifier in Huntington's disease. Neurogenetics (2005) 1.06
A polymorphism of the NFKBIA gene is associated with Crohn's disease patients lacking a predisposing allele of the CARD15 gene. Int J Colorectal Dis (2003) 1.05
Does glucocorticosteroid-resistant large-vessel vasculitis (giant cell arteritis and Takayasu arteritis) exist and how can remission be achieved? A critical review of the literature. Clin Exp Rheumatol (2012) 1.04
Autoantibodies against granulocyte colony-stimulating factor in Felty's syndrome and neutropenic systemic lupus erythematosus. Arthritis Rheum (2002) 1.04
A novel N-ethyl-N-nitrosourea-induced mutation in phospholipase Cγ2 causes inflammatory arthritis, metabolic defects, and male infertility in vitro in a murine model. Arthritis Rheum (2011) 1.04
Autoantibody detection using indirect immunofluorescence on HEp-2 cells. Ann N Y Acad Sci (2009) 1.04
Wegener's granulomatosis. Herz (2004) 1.02
Autosomal dominant hereditary spastic paraplegia: novel mutations in the REEP1 gene (SPG31). BMC Med Genet (2008) 1.02
Wegener's granulomatosis: antiproteinase 3 antibodies induce monocyte cytokine and prostanoid release-role of autocrine cell activation. J Leukoc Biol (2002) 1.02
Lifespan, lifetime reproductive performance and paternity loss of within-pair and extra-pair offspring in the coal tit Periparus ater. Proc Biol Sci (2009) 1.01
ASK1 and MAP2K6 as modifiers of age at onset in Huntington's disease. J Mol Med (Berl) (2008) 1.01
Expansion of circulating NKG2D+ effector memory T-cells and expression of NKG2D-ligand MIC in granulomaous lesions in Wegener's granulomatosis. Clin Immunol (2008) 1.01
Genetic analysis of candidate genes modifying the age-at-onset in Huntington's disease. Hum Genet (2006) 1.00
Treatment of ANCA-associated vasculitides (AAV). Autoimmun Rev (2012) 1.00
Clinical and immunological features of drug-induced and infection-induced proteinase 3-antineutrophil cytoplasmic antibodies and myeloperoxidase-antineutrophil cytoplasmic antibodies and vasculitis. Curr Opin Rheumatol (2010) 1.00
Value of anti-infective chemoprophylaxis in primary systemic vasculitis: what is the evidence? Arthritis Res Ther (2009) 0.99
Huntington's disease as caused by 34 CAG repeats. Mov Disord (2008) 0.99
Progranulin antibodies in autoimmune diseases. J Autoimmun (2012) 0.98
Granulomatosis with polyangiitis (Wegener's): an alternative name for Wegener's granulomatosis. J Am Soc Nephrol (2011) 0.98
Wegener autoantigen induces maturation of dendritic cells and licenses them for Th1 priming via the protease-activated receptor-2 pathway. Blood (2006) 0.97
Association of toll-interacting protein gene polymorphisms with atopic dermatitis. BMC Dermatol (2007) 0.97
[Structural change in the DGRh]. Z Rheumatol (2004) 0.96
Diagnostic significance of ANCA in vasculitis. Nat Clin Pract Rheumatol (2006) 0.96
Cellular and subcellular localization of Huntingtin [corrected] aggregates in the brain of a rat transgenic for Huntington disease. J Comp Neurol (2007) 0.96
PR3-ANCA: a promising biomarker for ulcerative colitis with extensive disease. Clin Chim Acta (2013) 0.96
Vasculitis in 2011: the renaissance of granulomatous inflammation in AAV. Nat Rev Rheumatol (2012) 0.96
Association of a common polymorphism in the promoter of UCP2 with susceptibility to multiple sclerosis. J Mol Med (Berl) (2005) 0.96
Genome-wide significant association of ANKRD55 rs6859219 and multiple sclerosis risk. J Med Genet (2013) 0.96
CCL17/thymus and activation-related chemokine in Churg-Strauss syndrome. Arthritis Rheum (2010) 0.95
Venous thromboembolism in Wegener's granulomatosis. J Rheumatol (2007) 0.95
Use of highly sensitive C-reactive protein for followup of Wegener's granulomatosis. J Rheumatol (2010) 0.95
Plasma cells within granulomatous inflammation display signs pointing to autoreactivity and destruction in granulomatosis with polyangiitis. Arthritis Res Ther (2014) 0.95
MANBA, CXCR5, SOX8, RPS6KB1 and ZBTB46 are genetic risk loci for multiple sclerosis. Brain (2013) 0.94
The low-penetrance R92Q mutation of the tumour necrosis factor superfamily 1A gene is neither a major risk factor for Wegener's granulomatosis nor multiple sclerosis. Ann Rheum Dis (2007) 0.94
Three novel mutations in the ACTA2 gene in German patients with thoracic aortic aneurysms and dissections. Eur J Hum Genet (2011) 0.94
Interleukin-15 stimulates macrophages to activate CD4+ T cells: a role in the pathogenesis of rheumatoid arthritis? Immunology (2008) 0.93
Successful use of bortezomib in a patient with systemic lupus erythematosus and multiple myeloma. Ann Rheum Dis (2010) 0.92
Risk factors and myocardial infarction in patients with obstructive sleep apnea: impact of beta2-adrenergic receptor polymorphisms. BMC Med (2007) 0.91
A Tyrosinase missense mutation causes albinism in the Wistar rat. Pigment Cell Res (2005) 0.91
Age at onset in Huntington's disease: replication study on the associations of ADORA2A, HAP1 and OGG1. Neurogenetics (2010) 0.90
Increased frequency of CCR4+ and CCR6+ memory T-cells including CCR7+CD45RAmed very early memory cells in granulomatosis with polyangiitis (Wegener's). Arthritis Res Ther (2012) 0.90
Update on clinical, pathophysiological and therapeutic aspects in ANCA-associated vasculitides. Curr Drug Discov Technol (2009) 0.90
Advances in the therapy of Wegener's granulomatosis. Curr Opin Rheumatol (2006) 0.90
Fine-structural analysis and connexin expression in the retina of a transgenic model of Huntington's disease. J Comp Neurol (2004) 0.90
mtDNA nt13708A variant increases the risk of multiple sclerosis. PLoS One (2008) 0.90
Nasal carriage of Staphylococcus aureus and endonasal activity in Wegener s granulomatosis as compared to rheumatoid arthritis and chronic Rhinosinusitis with nasal polyps. Clin Exp Rheumatol (2010) 0.89
Tumor suppressor role of phospholipase C epsilon in Ras-triggered cancers. Proc Natl Acad Sci U S A (2014) 0.89
Anti-proteinase 3 antibodies (c-ANCA) prime CD14-dependent leukocyte activation. J Leukoc Biol (2005) 0.89